Skinvisible Web Sign Up for Updates         T 702.433.7154   |   F 702.433.7192
Skinvisible - Polymer Delivery System

The Ultimate Polymer Delivery System.

Skinvisible Granted US Patent for Stabilizing Retinoids

Intellectual Property Portfolio Strengthens

Las Vegas, NV- November 27, 2012 - Skinvisible Pharmaceuticals, Inc. (SKVI:OTCBB & OTCQB) today announced that it has been granted US Patent Number 8,299,122 for combining retinoic acid with its patented polymer delivery system, Invisicare®. The patent issued by the United States Patent and Trademark Office (USPTO) entitled "Methods for Stabilizing Retinoids, Retinoid Containing Composition, and Methods of Using a Retinoid Containing Composition," will provide protection until April 14, 2029.

Retinoic acid (tretinoin) is a retinoid which is commonly used in prescription drugs to treat acne, psoriasis and skin cancer. Retinoids however degrade in the presence of light and oxygen. Skinvisible's invention stabilizes retinoic acid, enhancing the life and efficacy of compositions containing retinoic acid. Additionally this patent relates to a method for stabilizing a retinoid, and to a retinoid containing composition.

The granting of this retinoid patent further substantiates Skinvisible's findings that Invisicare provides major benefits to the topical formulations it develops. In addition to the stabilization of retinoic acid, Invisicare also controls the release of the active, providing a gradual release over time that can decrease irritation caused by the active ingredient. Since acne continues to be the largest prescription market in dermatology with estimated sales of US $2.3 billion worldwide, Skinvisible has developed three additional acne formulations adapalene, clindamycin and salicylic acid, all of which are available for exclusive licensing.

"We are pleased to receive this patent which increases the depth of intellectual property protection, especially as it pertains to our high-value acne formulations," said Terry Howlett, President and CEO. "This patent provides potential licensees with a further layer of exclusivity and will assist Skinvisible as it actively seeks partnering, licensing and co-development arrangements globally to maximize the potential of this recently issued patent."

Skinvisible continues to proactively build and strengthen its global patent portfolio for Invisicare as well as its forty plus prescription, over-the-counter and cosmeceutical formulations it has developed. Skinvisible has received patent approval for Invisicare in the following major countries: U.S.(2), Canada, Europe(4), Australia, India, Japan, China, Hong Kong and S. Korea and three product specific patents covering its dermal barrier products, sunscreen formulations and now retinoids. The Company expects to be granted additional patents shortly including further expansion of its Invisicare technology patents as well as valuable targets for dermatology products.

  Press Release Index
New Press Release Alerts:


Click here to join our mailing list.
Home    |     About us    |    Technology    |    Products    |    Investors    |    Contact Us    |    Disclaimer & Privacy    |     Sign Up for Updates
© 2008 Skinvisible Pharmaceuticals, Inc.     Note: This website is not intended for Canadian residents.